



LKT Laboratories, Inc.

AP-26113

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID A600002

CAS No. 1197958-12-5

Chemical Name

Synonym Brigatinib Analog, AP26113


Formula $C_{26}H_{34}ClN_6O_2P$

Formula Wt. 529.02

Melting Point

Purity $\geq 98\%$

Solubility



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
A600002	25 mg	\$133.60
A600002	100 mg	\$340.70

Store Temp -20°C

Ship Temp Ambient

Description AP-26113 (brigatinib) is a pan inhibitor of ALK. It is a leading candidate for the treatment of ALK+ non-small-cell lung cancer, especially those with major resistance mechanisms. AP-26113 exhibits efficacy against models of ALK+ anaplastic large cell lymphoma in cases where crizotinib, an approved drug for late-stage and metastatic lung cancers, fails due to developed drug resistance.

References Huang W., Liu S., et al. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. *J Med Chem* 59(10):4948-64 (2016). PMID: 27144831.

Ceccon M., Mologni L., et al. Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. *Mol Cancer Res.* 13(4):775;83 (2015). PMID: 25421750.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.